The cost effectiveness of adalimumab (HUMIRA®) in UK patients with moderate to severe RA

被引：0
|
作者：
Bansback, NJ
Brennan, A
Sengupta, N
Pang, F
机构：
[1] Univ Sheffield, Sheffield, S Yorkshire, England
[2] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2004年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：512 / 513
页数：2
相关论文
共 50 条
  • [41] Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain
    Schlueter, Max
    Finn, Elaine
    Diaz, Silvia
    Dilla, Tatiana
    Inciarte-Mundo, Jose
    Fakhouri, Walid
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2019, 11 : 395 - 403
  • [42] The cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in the UK
    Ara, R. M.
    Reynolds, A. V.
    Conway, P.
    RHEUMATOLOGY, 2007, 46 (08) : 1338 - 1344
  • [43] COST EFFECTIVENESS OF DIMETHYL FUMARATE (DMF) IN THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS: A UK PERSPECTIVE
    Naval, Maeso S.
    Casas, Ruiz L.
    Spackman, E.
    VALUE IN HEALTH, 2018, 21 : S427 - S427
  • [44] Cost-effectiveness of valdecoxib compared to diclofenac in patients with rheumatoid arthritis (RA) in the UK (UK) and Germany
    Alten, RH
    von Scheele, B
    Gaffney, L
    Maciver, F
    Niculescu, L
    VALUE IN HEALTH, 2004, 7 (06) : 664 - 664
  • [45] Remission and major clinical response in active rheumatoid arthritis (RA) patients after adalimumab (Humira®) treatment
    Burmester, G. M.
    Wordsworth, P.
    McKenna, F.
    Farraccioli, G. F.
    Flipo, R. -M.
    Kary, S.
    Kupper, H.
    RHEUMATOLOGY, 2007, 46 : I28 - I29
  • [46] IMPACT OF PATIENT SUPPORT PROGRAMS (PSP) OF ADALIMUMAB (HUMIRA®) ON BIOLOGICS ADHERENCE IN PATIENTS TREATED WITH ADALIMUMAB (HUMIRA®) IN ARGENTINA
    Luissi, Aurelia
    Gonzalez, Rosanna
    Pardal, Dario
    Cosentino, Vanesa
    Dantur, Gabriela
    Kanevsky, Diego
    Castillo, Leandro
    Roberto Soriano, Enrique
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2019, 25 : S82 - S82
  • [47] Remission and major clinical response in patients with active rheumatoid arthritis (RA) after treatment with adalimumab (Humira®).
    Burmester, G. M.
    Ferraccioli, G. F.
    Flipo, R-M
    Kary, S.
    Kupper, H.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S377 - S377
  • [48] Cost-Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate-Severe Crohn's Disease in Biologic-Naive Patients
    Aliyev, Elmar R.
    Hay, Joel W.
    Hwang, Caroline
    PHARMACOTHERAPY, 2019, 39 (02): : 118 - 128
  • [49] THE EFFECT OF DISEASE DURATION ON CLINICAL OUTCOMES FOLLOWING ADALIMUMAB (HUMIRA®) THERAPY IN RA
    Emery, P.
    Fleischmann, R.
    Strand, V.
    Reiss, W. G.
    Spencer-Green, G.
    Segurado, O. G.
    RHEUMATOLOGY, 2004, 43 : 38 - 39
  • [50] THE COST-EFFECTIVENESS OF USTEKINUMAB COMPARED TO INFLIXIMAB AND ADALIMUMAB IN ADULT PATIENTS WITH MODERATE-SEVERE CROHN'S DISEASE (TNF NAIVE POPULATION)
    Aliyev, E. R.
    Hay, J. W.
    Hwang, C.
    VALUE IN HEALTH, 2018, 21 : S84 - S84
12345